about
The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A ReviewA current update on the rule of alternative and complementary medicine in the treatment of liver diseasesDrug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.Pain management in the cirrhotic patient: the clinical challenge.A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsReview article: prescribing medications in patients with cirrhosis - a practical guide.Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation.Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines.Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.The effects of poor sleep quality on cognitive function of patients with cirrhosis.CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.Limited Knowledge of Acetaminophen in Patients with Liver Disease.Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update.Methylphenidate: established and expanding roles in symptom management.Drug interaction potential of resveratrol.Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.The pharmacology of novel oral anticoagulants.Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation.The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendationsPrescribing medications in patients with decompensated liver cirrhosis.Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol.Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease.Drug metabolism and liver disease: a drug-gene-environment interaction.A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.Hepatobiliary Quiz Answers-19 (2016)Biochemical mechanisms in drug-induced liver injury: certainties and doubts.Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations.Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.Pharmacokinetic changes after placement of a transjugular intrahepatic portosystemic shunt.Safe use of proton pump inhibitors in patients with cirrhosis.
P2860
Q26851158-C7C62C65-47EF-42F9-AA7C-9788759A00A3Q27012998-3F56B620-05D3-4910-A148-873D36113117Q30241648-A5AA9753-DA43-43D7-A57D-58032C83647DQ30277969-68F917D0-1810-4B48-94D3-F1258B912259Q30494286-953DDBEE-97B8-49CD-8398-0B7944FD8F32Q33721358-3C048A1E-B310-4746-AD03-008BA6D694F4Q33763177-DB2D89CE-BDE7-4051-AD5B-EA370A971A31Q34342554-277A9494-599D-4107-A04E-D9613D8B50FCQ35087638-98BEA2E6-B39E-44EB-95D3-ABE89132D028Q36414936-4CE2993D-F924-439B-98CE-E53C928DA038Q37336958-433534B3-8B60-4534-8E61-82A3D5246F53Q37355935-142C129C-6C83-4E9A-9EB5-B1409763884FQ37405826-6B7DB6D3-65AB-4C60-921F-39F3AA3ACC7EQ37492051-3CE0C51C-9657-4BEA-8580-20287B2968FCQ37578276-8601F30B-96A8-40C0-8A08-C56B20DBB5A5Q37603899-D57122AE-3C09-4FE1-A120-726E3EC75CF1Q37770251-FBE83EBB-8B18-4E6B-82A3-70906E954A1AQ37965133-E8E08F21-7F28-48D7-99BA-AD9CAB93FA3EQ38025685-03FEF26B-FDEE-4AAC-9213-9FE3BF115A71Q38079779-E7C2D2C4-BF6B-4477-9C09-D9BF9AF7E4CCQ38122099-9FC00CA6-EF46-4FB4-8484-88AE5469331AQ38245124-113439C7-4598-4253-BF4C-C3BC8CBCC92DQ38283546-1C133B70-A99F-447A-969B-875F5CB780BEQ38345809-269A11C9-7A0C-4B8C-B49F-0713502ED56BQ38809021-B94797AA-0266-4D95-B9BF-A387F4008D47Q38811345-5E5F0DF6-9614-4678-8730-DF572BFC5D45Q39037269-2EFD8530-540C-44CF-8D15-2ED35D65CCA1Q40839485-6FC63569-4194-47BB-8C6F-458D97B2FD1CQ41342190-7CA0ACA9-3C41-44E5-98A0-252DDCB9BED7Q42588200-BD69DF32-50EB-47CC-9EE8-50DD08F466CFQ43230727-1660CE1E-19C2-4B13-A1C3-3063F93A0387Q44053384-CEB94338-31B7-4620-8F90-D97EF2F99A9FQ44097278-4C3B5435-655E-41AE-AC04-2C4678F61023Q46301471-71C8F82C-8697-4097-9B16-70389B5AE3F1Q50057713-97947E53-A663-40FD-8B74-F3708959FB1FQ50793400-C64F5ADB-4D21-44BC-ABF7-E6EFDCF10B9FQ54420166-664A0927-A9AC-40D7-B754-CED83980643BQ55718075-4EE6091C-9CDF-4AAC-826A-559B0BB0BB4B
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Dose adjustment in patients with liver disease
@ast
Dose adjustment in patients with liver disease
@en
Dose adjustment in patients with liver disease
@nl
type
label
Dose adjustment in patients with liver disease
@ast
Dose adjustment in patients with liver disease
@en
Dose adjustment in patients with liver disease
@nl
prefLabel
Dose adjustment in patients with liver disease
@ast
Dose adjustment in patients with liver disease
@en
Dose adjustment in patients with liver disease
@nl
P2093
P3181
P1433
P1476
Dose adjustment in patients with liver disease
@en
P2093
Fabiola Delcò
Jürgen Drewe
Lydia Tchambaz
Raymond Schlienger
Stephan Krähenbühl
P304
P3181
P356
10.2165/00002018-200528060-00005
P407
P577
2005-01-01T00:00:00Z
P5875
P6179
1013711108